Computational Prediction of Neutralization Epitopes Targeted by Human Anti-V3 HIV Monoclonal Antibodies

被引:8
|
作者
Shmelkov, Evgeny [1 ]
Krachmarov, Chavdar [2 ]
Grigoryan, Arsen V. [1 ]
Pinter, Abraham [2 ]
Statnikov, Alexander [3 ]
Cardozo, Timothy [1 ]
机构
[1] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10003 USA
[2] Rutgers New Jersey Med Sch, Publ Hlth Res Inst Ctr, Newark, NJ USA
[3] NYU, Sch Med, Ctr Hlth Informat & Bioinformat, New York, NY USA
来源
PLOS ONE | 2014年 / 9卷 / 02期
基金
美国国家卫生研究院;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; BROAD NEUTRALIZATION; CROSS-REACTIVITY; STRUCTURAL BASIS; BINDING MODE; VACCINE; GP120; COMPLEX; DESIGN; CONFORMATION;
D O I
10.1371/journal.pone.0089987
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The extreme diversity of HIV-1 strains presents a formidable challenge for HIV-1 vaccine design. Although antibodies (Abs) can neutralize HIV-1 and potentially protect against infection, antibodies that target the immunogenic viral surface protein gp120 have widely variable and poorly predictable cross-strain reactivity. Here, we developed a novel computational approach, the Method of Dynamic Epitopes, for identification of neutralization epitopes targeted by anti-HIV-1 monoclonal antibodies (mAbs). Our data demonstrate that this approach, based purely on calculated energetics and 3D structural information, accurately predicts the presence of neutralization epitopes targeted by V3-specific mAbs 2219 and 447-52D in any HIV-1 strain. The method was used to calculate the range of conservation of these specific epitopes across all circulating HIV-1 viruses. Accurately identifying an Ab-targeted neutralization epitope in a virus by computational means enables easy prediction of the breadth of reactivity of specific mAbs across the diversity of thousands of different circulating HIV-1 variants and facilitates rational design and selection of immunogens mimicking specific mAb-targeted epitopes in a multivalent HIV-1 vaccine. The defined epitopes can also be used for the purpose of epitope-specific analyses of breakthrough sequences recorded in vaccine clinical trials. Thus, our study is a prototype for a valuable tool for rational HIV-1 vaccine design.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies
    Shen, Guomiao
    Upadhyay, Chitra
    Zhang, Jing
    Pan, Ruimin
    Zolla-Pazner, Susan
    Kong, Xiang-Peng
    Hioe, Catarina E.
    PLOS ONE, 2015, 10 (10):
  • [32] Fate of anti-gp120 and anti-V3 antibodies (Abs) during therapy of HIV infection with Indinavir.
    Morrison, SA
    Govek, EE
    Shen, Y
    Steigbigel, RT
    CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 128 - 128
  • [33] A computationally designed immunogen elicits potent anti-V3 neutralizing antibodies
    Carrico, C. T.
    Lagerquist, E.
    Boni, E.
    Ban, Y. A.
    Bretz, C.
    Ellingson, K.
    Kalyuzhniy, O.
    Montefiori, D.
    Strong, R.
    Stamatatos, L.
    Schief, W.
    RETROVIROLOGY, 2009, 6
  • [34] Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding
    Maruta, Yasuhiro
    Kuwata, Takeo
    Tanaka, Kazuki
    Alam, Muntasir
    Valdez, Kristel Paola Ramirez
    Egami, Yoshika
    Suwa, Yoshiaki
    Morioka, Hiroshi
    Matsushita, Shuzo
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2016, 69 (05) : 395 - 404
  • [35] LACK OF ASSOCIATION BETWEEN ANTI-V3 LOOP ANTIBODIES AND PERINATAL TRANSMISSION OF HIV-1 IN KAMPALA, UGANDA
    EPSTEIN, H
    GUAY, L
    HOM, D
    MMIRO, F
    NDUGWA, C
    MARUM, L
    OLNESS, K
    PIWOWAR, E
    KATAAHA, P
    BAENZIGER, J
    JACKSON, JB
    PEDIATRIC AIDS AND HIV INFECTION-FETUS TO ADOLESCENT, 1994, 5 (06): : 350 - 356
  • [36] Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures
    Metlas, R
    Trajkovic, D
    Srdic, T
    Veljkovic, V
    Colombatti, A
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (04) : 266 - 270
  • [37] Neutralization Potential of the Plasma of HIV-1 Infected Indian Patients in the Context of Anti-V3 Antibody Content and Antiretroviral Theraphy
    Choudhary, Alok Kumar
    Andrabi, Raiees
    Prakash, Somi Sankaran
    Kumar, Rajesh
    Choudhury, Shubhasree Dutta
    Wig, Naveet
    Biswas, Ashutosh
    Hazarika, Anjali
    Luthra, Kalpana
    JOURNAL OF MICROBIOLOGY, 2012, 50 (01) : 149 - 154
  • [38] Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral theraphy
    Alok Kumar Choudhary
    Raiees Andrabi
    Somi Sankaran Prakash
    Rajesh Kumar
    Shubhasree Dutta Choudhury
    Naveet Wig
    Ashutosh Biswas
    Anjali Hazarika
    Kalpana Luthra
    The Journal of Microbiology, 2012, 50 : 149 - 154
  • [39] Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies
    Hioe, CE
    Xu, S
    Chigurupati, P
    Burda, S
    Williams, C
    Gorny, MK
    ZollaPazner, S
    INTERNATIONAL IMMUNOLOGY, 1997, 9 (09) : 1281 - 1290
  • [40] IDENTIFICATION OF AN N-LINKED GLYCAN IN THE V1-LOOP OF HIV-1 GP120 INFLUENCING NEUTRALIZATION BY ANTI-V3 ANTIBODIES AND SOLUBLE CD4
    BLOMSTEDT, A
    GRAM, G
    HEMMING, A
    JANSSON, B
    AKERBLOM, L
    NIELSEN, JO
    HANSEN, JE
    OLOFSSON, S
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 216 - 216